Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes

 
• By Vibha Ravi
  
Aragen CEO Manni Kantipudi
Aragen CEO Manni Kantipudi discussed US tariffs, manufacturing shifts, regulation and other issues. (Aragen Life Sciences)

More from R&D

More from Interviews